Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYLilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic DermatitisPREV STORYADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™